Literature DB >> 17349856

Neurobiology of dopamine in schizophrenia.

Olivier Guillin1, Anissa Abi-Dargham, Marc Laruelle.   

Abstract

This chapter is an update on the dopamine (DA) imbalance in schizophrenia, including the evidence for subcortical hyperstimulation of D2 receptors underlying positive symptoms and cortical hypodopaminergia-mediating cognitive disturbances and negative symptoms. After a brief review of the anatomical neurocircuitry of this transmitter system as a background, we summarize the evidence for dopaminergic alterations deriving from pharmacological, postmortem, and imaging studies. This evidence supports a prominent role for D2 antagonism in the treatment of positive symptoms of schizophrenia and strongly suggests the need for alternative approaches to address the more challenging problem of negative symptoms and cognitive disturbances.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17349856     DOI: 10.1016/S0074-7742(06)78001-1

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  91 in total

Review 1.  Dopaminergic dysfunction in schizophrenia: salience attribution revisited.

Authors:  Andreas Heinz; Florian Schlagenhauf
Journal:  Schizophr Bull       Date:  2010-05-07       Impact factor: 9.306

Review 2.  From reinforcement learning models to psychiatric and neurological disorders.

Authors:  Tiago V Maia; Michael J Frank
Journal:  Nat Neurosci       Date:  2011-02       Impact factor: 24.884

3.  Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine.

Authors:  Kathleen S Alexander; Hui-Qiu Wu; Robert Schwarcz; John P Bruno
Journal:  Psychopharmacology (Berl)       Date:  2011-10-26       Impact factor: 4.530

Review 4.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

5.  AGAP1/AP-3-dependent endocytic recycling of M5 muscarinic receptors promotes dopamine release.

Authors:  Jacob Bendor; José E Lizardi-Ortiz; Robert I Westphalen; Markus Brandstetter; Hugh C Hemmings; David Sulzer; Marc Flajolet; Paul Greengard
Journal:  EMBO J       Date:  2010-07-27       Impact factor: 11.598

Review 6.  N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?

Authors:  Joshua T Kantrowitz; Daniel C Javitt
Journal:  Brain Res Bull       Date:  2010-04-24       Impact factor: 4.077

Review 7.  Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions.

Authors:  Deanna M Barch; Erin C Dowd
Journal:  Schizophr Bull       Date:  2010-06-21       Impact factor: 9.306

8.  Conceptualization and treatment of negative symptoms in schizophrenia.

Authors:  Sonali Sarkar; Kiley Hillner; Dawn I Velligan
Journal:  World J Psychiatry       Date:  2015-12-22

9.  Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies.

Authors:  Paolo Fusar-Poli; Andreas Meyer-Lindenberg
Journal:  Schizophr Bull       Date:  2012-01-26       Impact factor: 9.306

10.  Childhood trauma and prodromal symptoms among individuals at clinical high risk for psychosis.

Authors:  Judy L Thompson; Meredith Kelly; David Kimhy; Jill M Harkavy-Friedman; Shamir Khan; Julie W Messinger; Scott Schobel; Ray Goetz; Dolores Malaspina; Cheryl Corcoran
Journal:  Schizophr Res       Date:  2009-01-25       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.